

TiGenix invited to present Cx611 Phase IIa data in plenary session of American College of Rheumatology and participating in other upcoming key conferences

Leuven (BELGIUM) – September 10, 2013 – TiGenix (NYSE Euronext: TIG), a leader in the field of cell therapy, announced today that it has been invited to present the results of its Phase IIa study of Cx611 in refractory rheumatoid arthritis in a plenary session of the American College of Rheumatology Annual Meeting on October 29. Furthermore, during the second half of 2013, the company will be present at a number of key events in Europe and the U.S. geared at investor, industry, and academic audiences to highlight the commercial potential of ChondroCelect®, the first approved cell therapy in Europe, and of the company's proprietary allogeneic stem cell programs. TiGenix's lead product Cx601 is currently in Phase III for perianal fistulas in Crohn's disease patients.

September 15- 18

ICRS 2013, Izmir, Turkey

TiGenix Satellite Symposium – Science & evidence in knee cartilage therapy: “Mind the Gap: Quick Fix vs. Durable Repair”

Chair: Tim Spalding (UK) MBBS, FRCS, FRCS Orth. Specialist Knee Surgeon, University Hospitals Coventry and Warwickshire NHS Trust. Honorary Associate Professor, Warwick Medical School, University of Warwick

Presenters: Philipp Niemeyer, Department of Orthopaedic Surgery and Traumatology, Freiburg University Hospital, Freiburg, Germany; Peter Verdonk, Professor of Orthopaedics and Traumatology, Ghent University, Belgium

Date & time: Tuesday, September 17, 1-2 PM

September 17-19

BioPharm America 2013, Westin Boston Waterfront Hotel, Boston, USA

Attendee: Claudia Jimenez, Senior Director Business Development

October 2-3

13th Large & Midcap Event, Palais Brongniart, Paris, France

Attendee: Claudia D'Augusta, CFO

October 14-16

Stem Cell Meeting on the Mesa, La Jolla, California, USA

Presenter: Eduardo Bravo, CEO

October 23-25

The World Conference on Regenerative Medicine, Congress Center Leipzig, Germany

Presenter: Guido Schopen, VP Medical Affairs & Commercial Operations

October 25-28

European Society of Gene and Cell Therapy (ESGCT) Collaborative Congress '13, Palacio Municipal de Congresos, Madrid, Spain

Presenters: Wilfried Dalemans, CTO & María Pascual, VP Clinical Operations and Regulatory Affairs



October 25-30

American College of Rheumatology (ACR) Annual Meeting 2013, San Diego, California, USA
Presenter: Dr. José María Álvaro-Gracia, MD, PhD, Head of the Biological Therapies Unit, Hospital Universitario de La Princesa, Madrid, Spain
Session Name: ACR Plenary Session III: Discovery 2013
Presentation: Phase Ib/IIa Study On Intravenous Administration Of Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells In Refractory Rheumatoid Arthritis Patients
Date & time: Tuesday, October 29, 2013: 11:00 AM-12:30 PM

November 4-6

BIO-Europe 2013, Messe Wien Exhibition and Congress Center, Vienna, Austria
Attendee: Claudia Jimenez, Senior Director Business Development

November 14

2nd Edition Belgian Biotech & Pharma Seminar, The Grand Hyatt, New York, USA
Attendee: Eduardo Bravo, CEO

November 21-24

IFATS meeting, Conrad New York, USA
Presenter: Dr. Gonzalez-Argente, MD, Head of Surgery Department, Hospital Universitari Son Espases, Palma, Spain
Presentation: Expanded allogeneic adipose-derived stem cells for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter Phase I/IIa clinical trial
Date & time: Saturday, November 23: 8:12 AM

Presenter: Eleuterio Lombardo, Scientific Director TiGenix
Presentation: Intralymphatic administration of adipose mesenchymal stem cells shows therapeutic effect in experimental colitis and arthritis
Date & time: Saturday, November 23, 3 PM

For more information:

Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com

Claudia D'Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com

Hans Herklots
Director Investor & Media Relations
hans.herklots@tigenix.com
+32 16 39 60 97

About TiGenix

TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown

TIGENIX

risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.